S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Opportunities to Optimize Cancer Policies Panel Discussion

The Interventional Pharmacoeconomic Toolbox Panel Discussion

May

Today In Oncology

USPSTF Issues Final Recommendation Statement on Screening for Breast Cancer

Relapsed or Refractory CD7-Positive Leukemia or Lymphoma CAR T-Cell Therapy Plus HSCT Without GVHD Prophylaxis

Premastectomy Radiotherapy, Surgery, and Immediate Breast Reconstruction

Liposomal Irinotecan vs Topotecan in Relapsed Small Cell Lung Cancer

Smoking Cessation Regimens: Does Dose of Therapy Matter?

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Related Videos

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Opportunities to Optimize Cancer Policies Panel Discussion

The Interventional Pharmacoeconomic Toolbox Panel Discussion

USPSTF Issues Final Recommendation Statement on Screening for Breast Cancer

Relapsed or Refractory CD7-Positive Leukemia or Lymphoma CAR T-Cell Therapy Plus HSCT Without GVHD Prophylaxis

Premastectomy Radiotherapy, Surgery, and Immediate Breast Reconstruction

Liposomal Irinotecan vs Topotecan in Relapsed Small Cell Lung Cancer

Smoking Cessation Regimens: Does Dose of Therapy Matter?